Zhou Kali, Dodge Jennifer L, Xu Edison, Emamaullee Juliet, Kahn Jeffrey A
Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Clin Transplant. 2022 Feb;36(2):e14527. doi: 10.1111/ctr.14527. Epub 2021 Nov 16.
Historically, patients with primary biliary cholangitis (PBC) experience waitlist mortality and low rates of liver transplant (LT). Herein, the impact of MELD-Na based allocation on PBC waitlist mortality was examined.
Adult patients with PBC were compared to those with alcohol-related liver disease (ALD) or non-alcoholic steatohepatitis (NASH) listed for LT from 2013 to 2019 in OPTN. Competing risk regression evaluated waitlist mortality in the MELD and MELD-Na eras using propensity score weights.
Overall, 1508 patients with PBC, 13581 with ALD, and 10455 with NASH were examined. In the MELD-Na era, 24-month cumulative incidence of waitlist mortality for PBC was 23.0% (95%CI 19.7-26.5%), ALD 13.9% (95%CI 13.1-14.8%), and NASH 20.0% (95%CI 18.9-21.2%). Using propensity score weights, adjusted risk of waitlist mortality was higher for PBC versus ALD (HR = 1.45, 95%CI 1.22-1.71) and NASH (HR = 1.32, 95%CI 1.14-1.55). Furthermore, among PBC, waitlist mortality risk per five-point elevation in MELD-Na (HR = 1.22, 95%CI 1.11-1.35) and Karnofsky score ≤30% (HR = 2.02, 95%CI 1.39-2.92) was significantly higher than among ALD (HR = 1.08, 95%CI 1.04-1.13; HR = 1.28, 95%CI 1.10-1.49) and NASH (HR = 1.05, 95%CI 1.00-1.09; HR = 1.16, 95%CI .99-1.37; all P-interactions < .05).
The MELD-Na score continues to underestimate risk of waitlist death for patients with PBC relative to ALD and NASH and highlights need for additional score modifications or exceptions.
从历史上看,原发性胆汁性胆管炎(PBC)患者存在等待名单上的死亡情况以及肝移植(LT)率较低的问题。在此,研究了基于终末期肝病模型(MELD)-钠评分的分配对PBC等待名单上死亡率的影响。
将2013年至2019年在美国器官共享联合网络(OPTN)中等待LT的成年PBC患者与酒精性肝病(ALD)或非酒精性脂肪性肝炎(NASH)患者进行比较。竞争风险回归使用倾向评分权重评估了MELD和MELD-钠评分时代的等待名单死亡率。
总体上,共检查了1508例PBC患者、13581例ALD患者和10455例NASH患者。在MELD-钠评分时代,PBC患者等待名单上24个月的累积死亡率为23.0%(95%置信区间19.7-26.5%),ALD患者为13.9%(95%置信区间13.1-14.8%),NASH患者为20.0%(95%置信区间18.9-21.2%)。使用倾向评分权重,PBC患者等待名单上死亡的调整风险高于ALD患者(风险比[HR]=1.45,95%置信区间1.22-1.71)和NASH患者(HR=1.32,95%置信区间1.14-1.55)。此外,在PBC患者中,MELD-钠评分每升高5分的等待名单死亡风险(HR=1.22,95%置信区间1.11-1.35)和卡诺夫斯基评分≤30%的风险(HR=2.02,95%置信区间1.39-2.92)显著高于ALD患者(HR=1.08,95%置信区间1.04-1.13;HR=1.28,95%置信区间1.10-1.49)和NASH患者(HR=1.05,95%置信区间1.00-1.09;HR=1.16,95%置信区间0.99-1.37;所有P交互作用<0.05)。
相对于ALD和NASH患者,MELD-钠评分继续低估了PBC患者等待名单上死亡的风险,并突出了进一步修改评分或制定例外情况的必要性。